NeoGenomics, Inc. - Common Stock (NQ:NEO)

17.25 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 16, 2022

Via ACCESSWIRE

NeoGenomics: Q2 Earnings Insights ↗

August 12, 2022

NeoGenomics (NASDAQ:NEO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For August 12, 2022 ↗

August 12, 2022

Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.

Via Benzinga

What 4 Analyst Ratings Have To Say About NeoGenomics ↗

August 10, 2022

NeoGenomics (NASDAQ:NEO) has observed the following analyst ratings within the last quarter:

Via Benzinga

NeoGenomics: Q2 Earnings Insights ↗

August 09, 2022

NeoGenomics (NASDAQ:NEO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

NeoGenomics Reports Revenue of $125 Million in the Second Quarter

August 09, 2022

Via ACCESSWIRE

NeoGenomics Announces Chief Executive Officer Appointment

July 21, 2022

Via ACCESSWIRE

NeoGenomics Announces Chief Executive Officer Appointment

July 21, 2022

Chris Smith named CEO effective August 15, 2022; Interim CEO Lynn Tetrault to resume role of independent Chair of the Board

From NeoGenomics, Inc.

Via AccessWire

NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022

July 15, 2022

FT. MYERS, FL / ACCESSWIRE / July 15, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to...

From NeoGenomics, Inc.

Via AccessWire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors

June 27, 2022

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors

June 24, 2022

From Law Offices of Howard G. Smith

Via Business Wire

Analyst Ratings for NeoGenomics ↗

April 28, 2022

Analysts have provided the following ratings for NeoGenomics (NASDAQ:NEO) within the last quarter:

Via Benzinga

NeoGenomics: Q1 Earnings Insights ↗

April 27, 2022

NeoGenomics (NASDAQ:NEO) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

The Law Offices of Frank R. Cruz Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors

June 24, 2022

From Law Offices of Frank R. Cruz

Via Business Wire

NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer

June 21, 2022

FT. MYERS, FL / ACCESSWIRE / June 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today confirms...

From NeoGenomics, Inc.

Via AccessWire

Lost Money in NeoGenomics, Inc.?

June 03, 2022

From Gibbs Law Group

Via Business Wire

NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences

June 03, 2022

FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...

From NeoGenomics, Inc.

Via AccessWire

Analyst Ratings for NeoGenomics ↗

June 03, 2022

Over the past 3 months, 10 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗

June 03, 2022

Via Benzinga

NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory

June 03, 2022

CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&D

From NeoGenomics, Inc.

Via AccessWire

NASDAQ:NEO Investor Alert: Investigation over Possible Wrongdoing at NeoGenomics, Inc. ↗

June 02, 2022

San Diego, CA -- (SBWIRE) -- 06/02/2022 -- Certain directors of NeoGenomics, Inc. are under investigation concerning potential breaches of fiduciary duties.

Via SBWire

Lost Money in NeoGenomics, Inc.?

May 24, 2022

From Gibbs Law Group

Via Business Wire

Lost Money in NeoGenomics, Inc.?

May 16, 2022

From Gibbs Law Group

Via Business Wire

NeoGenomics Appoints Lynn Tetrault Interim CEO

May 16, 2022

FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services,...

From NeoGenomics, Inc.

Via AccessWire

Earnings Scheduled For May 13, 2022 ↗

May 13, 2022

Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is estimated to report quarterly loss at $0.13 per share on revenue of $20.08 million.

Via Benzinga

NeoGenomics, Inc. (NASDAQ: NEO) Investor Notice: Investigation over Possible Violations of Securities Laws ↗

May 11, 2022

San Diego, CA -- (SBWIRE) -- 05/11/2022 -- NeoGenomics, Inc is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting

May 10, 2022

FT. MYERS, FL / ACCESSWIRE / May 10, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...

From NeoGenomics, Inc.

Via AccessWire

NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary

May 09, 2022

FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the...

From NeoGenomics, Inc.

Via AccessWire

NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference

May 05, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

From NeoGenomics, Inc.

Via AccessWire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 29, 2022

Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.